Simplify Logo

Full-Time

Assistant Controller/Accounting Director

Confirmed live in the last 24 hours

Alamar Biosciences

Alamar Biosciences

51-200 employees

Develops technology for protein detection and measurement

Hardware
Biotechnology

Compensation Overview

$180k - $200kAnnually

+ Bonus + Equity + Benefits

Senior, Expert

Fremont, CA, USA

Category
Cost Accounting
Financial Accounting
Management Accounting
Accounting
Required Skills
NetSuite
Requirements
  • Bachelor's degree in Accounting, Finance, or related field
  • 7+ years of experience in a finance or accounting role with substantial management and operational exposure
  • Strong knowledge of GAAP and financial reporting standards
  • Proficiency in Microsoft Office and Netsuite
  • Excellent analytical and problem-solving skills
  • Strong communication and interpersonal skills
  • Ability to work independently and as part of a team
  • Has the ability to handle multiple high priority projects with accuracy
Responsibilities
  • Oversee the financial close process, ensuring accurate recording of transactions (including journal entries, accruals, reconciliations and consolidation)
  • Assist with the preparation of monthly, quarterly, and annual consolidated financial statements
  • Manage inventory and related cost accounting
  • Prepare and analyze complex financial and operational data and provide accurate and timely financial recommendations for decision-making purposes and strategic initiatives
  • Stays current with all applicable accounting, tax and other regulations and requirements, adapting policies and practices accordingly
  • Assist with the implementation and maintenance of internal controls
  • Support the Controller with audit preparations, technical memo drafting, and compliance
  • Manage accounting team members
  • Other duties as assigned

Alamar Biosciences focuses on the study of proteins, known as proteomics, to enhance disease detection and treatment. The company has created NULISA™, a technology that can detect and measure proteins in the human body with high sensitivity and a wide range. This allows researchers and clinicians to profile clinically relevant protein biomarkers, which are essential for developing new diagnostic tests and treatments for various diseases. Alamar's ARGO™ system complements NULISA™ by providing a fully automated, high-throughput platform for precision proteomics. Unlike many competitors, Alamar's technology simplifies the process, reducing the need for extensive technical expertise, making it accessible to a broader range of clients. The goal of Alamar Biosciences is to improve our understanding of proteins in health and disease, ultimately leading to better early detection and treatment options.

Company Stage

Series C

Total Funding

$224.3M

Headquarters

Hayward, California

Founded

2018

Growth & Insights
Headcount

6 month growth

23%

1 year growth

37%

2 year growth

115%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $128 million Series C financing round positions Alamar for accelerated growth and commercialization of its proteomics platform.
  • The launch of innovative products like the NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assay demonstrates Alamar's commitment to advancing disease research and diagnostics.
  • Collaborations with leading organizations in aging and neurodegenerative disease research could lead to groundbreaking discoveries and new market opportunities.

What critics are saying

  • The highly competitive biotechnology sector requires continuous innovation to maintain a leading position.
  • Dependence on strategic partnerships and collaborations may pose risks if these relationships falter or fail to deliver expected outcomes.

What makes Alamar Biosciences unique

  • Alamar BioSciences' NULISA™ technology offers unprecedented sensitivity and range in protein detection, setting it apart from traditional proteomics solutions.
  • The ARGO™ system's fully automated, high-throughput capabilities reduce the need for technical expertise, making it more accessible to a broader range of clients.
  • Strategic partnerships, such as with the Biomarkers of Aging Consortium and ALZpath, enhance Alamar's credibility and expand its research applications.